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OBJECTIVES: FTY720 modulates CD4+T cells by the augmentation of regulatory T cell activity, secretion of
suppressive cytokines and suppression of IL-17 secretion by Th17 cells. To further understand the process of graft
rejection/acceptance, we evaluated skin allograft survival and associated events after FTY720 treatment.
METHODS: F1 mice (C57BL/6xBALB/c) and C57BL/6 mice were used as donors for and recipients of skin
transplantation, respectively. The recipients were transplanted and either not treated or treated with FTY720 by
gavage for 21 days to evaluate the allograft survival. In another set of experiments, the immunological evaluation
was performed five days post-transplantation. The spleens, axillary lymph nodes and skin allografts of the recipient
mice were harvested for phenotyping (flow cytometry), gene expression (real-time PCR) and cytokine (Bio-Plex)
analysis.
RESULTS: The FTY720 treatment significantly increased skin allograft survival, reduced the number of cells in the
lymph nodes and decreased the percentage of Tregs at this site in the C57BL/6 recipients. Moreover, the treatment
reduced the number of graft-infiltrating cells and the percentage of CD4+ graft-infiltrating cells. The cytokine
analysis (splenocytes) showed decreased levels of IL-10, IL-6 and IL-17 in the FTY720-treated mice. We also observed
a decrease in the IL-10, IL-6 and IL-23 mRNA levels, as well as an increase in the IL-27 mRNA levels, in the splenocytes
of the treated group. The FTY720-treated mice exhibited increased mRNA levels of IL-10, IL-27 and IL-23 in the skin
graft.
CONCLUSIONS: Our results demonstrated prolonged but not indefinite skin allograft survival by FTY720 treatment.
This finding indicates that the drug did not prevent the imbalance between Tr1 and Th17 cells in the graft that led
to rejection.
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INTRODUCTION
The rejection responses to allografts are initiated by a
specific T-cell recognition of antigens expressed on the cells
within the graft (1-3). T-cell activation after allograft
transplantation requires both antigen presentation and co-
stimulatory signals (4,5), and, once they occur, several other
factors are involved, leading to effector or regulatory
immune responses. Recently, the immune responses to
allografts have been reported to be modulated by regulatory
T cells, such as CD4+CD25+ T cells, which comprise 5-10% of
the peripheral CD4+ T cells in adult rodents and humans (6).
These cells play an important role in the maintenance of
self-tolerance, prevention of autoimmune diseases (7), and
regulation of allogeneic immune responses (8,9).
Regulatory natural T cells (nTregs) are generated in the
thymus, defined by their high expression of the IL-2 receptor
a chain (CD25) and thought to be controlled by the forkhead
box P3 (Foxp3) transcription factor. The population of
thymus-derived Treg cells is supplemented with a popula-
tion of inducible Tregs (iTregs) generated from naı¨ve T cells
activated in the presence of TGF-b. iTregs are believed to be
functionally similar to thymus-derived nTregs (10).
In contrast with Treg-generated transplantation tolerance,
the Th17 cell population has been associated with allograft
rejection (11). Th17s are described as T cells producing
interleukin-17 that are dependent on signals from cytokines,
such as IL-6 (12). Moreover, the Th17 response is propa-
gated by the cytokines IL-23 and IL-21 (13,14).
Copyright  2012 CLINICS – This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
No potential conflict of interest was reported.
CLINICS 2012;67(7):805-813 DOI:10.6061/clinics/2012(07)17
805
A member of the IL-12 family of cytokines, namely IL-27,
has been shown to cause the immune-specific suppression of
IL-17 secretion by down-regulating retinoid orphan nuclear
receptor C expression. This inhibition is associated with the
induction of the intracellular signaling factor STAT1 and the
suppression of cytokine signaling protein 1 (15).
Investigations of the Treg-Th17 axis aim to identify poten-
tial pharmacological targets to promote graft acceptance.
The new compound FTY720 binds to S1P (sphingosine-1
phosphate) receptors, causing lymphocytes to be seques-
tered in secondary lymphoid organs. In addition, FTY720
inhibits the egress of lymphocytes from the thymus and
secondary lymphoid tissues into the periphery, thereby
preventing the migration of lymphocytes to inflammatory
sites (16,17). Some additional mechanisms of action have
been proposed for FTY720, such as its anti-proliferative
effect on T cells through the augmentation of regulatory T
cell activity and secretion of suppressive cytokines (18-20).
FTY720 has also been shown to cause the suppression of IL-
17 secretion by Th17 cells in vitro (15).
Jin et al. (21) showed that, although FTY720 improved
CD4CD25Foxp3 expression after skin transplantation, the
monotherapy was not sufficient to prevent rejection. How-
ever, when MR1 (anti-CD154 mAb) was administered in
combination with FTY720, skin allograft survival increased.
Interestingly, the expression of CD4CD25Foxp3 was similar
when FTY720 monotherapy was compared with FTY720+
MR1. These findings suggest that mechanisms other than
CD4CD25Foxp3 expression occur during allograft accep-
tance. To further understand the process of graft accep-
tance/rejection, we evaluated skin allograft survival and
associated events following treatment with FTY720.
MATERIALS AND METHODS
Experimental groups
Mice were cared for in accordance with the Principles of
Laboratory Animal Care (NIH publication 86-23, revised
1985) and the regulations of the Brazilian Committee on
Animal Experimentation. The project was submitted to and
approved by the Animal Ethic Committee of UNIFESP
Federal University of Sa˜o Paulo (protocol 0125/08).
Eight- to ten-week-old male (C57BL/6xBALB/c) F1 and
C57BL/6 mice were used as donors for and recipients of
Figure 1 - FTY720 treatment prolongs mouse skin allograft survival. F1 (BALB/c x C57BL/6) mice were donors to C57BL/6 recipients, and
skin allograft rejection was determined macroscopically when the graft reached a necrosis level of 90%. A - Kaplan-Meier curve of skin
allograft survival showing that FTY720 treatment significantly increased the survival of F1 (BALB/c x C57BL/6) skin allografts in the
C57BL/6 recipients. B - The macroscopic signs of rejection were observed as early as day 7 in transplanted, non-treated (Tx) mice. C -
Rejection signs occurred later in the transplanted, FTY720-treated (Tx+FTY) mice.
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skin transplantation, respectively. Skin from the donor tail
(1.0 cm2) was placed on the C57BL/6 mice and fixed with 6-
0 nylon sutures (Brasuture, Brazil) at each corner. The
recipient mice were either transplanted only (Tx, n = 5) or
transplanted and submitted to the daily administration of
FTY720 (Novartis, Switzerland; 1 mg/kg/day diluted in
distilled water) by gavage for 21 days, starting three days
before the transplantation (Tx + FTY, n= 5). The grafts were
observed daily to establish skin allograft survival (rejec-
tion = 90% skin necrosis). In another set of experiments, the
immunological evaluation was performed five days post-
transplantation.
Experimental design
1) To evaluate skin allograft survival, the following steps
were completed: FTY720 treatment, skin transplantation,
and graft follow-up.
2) An immunological evaluation of C57BL/6-transplanted
mice either treated or not treatedwith FTY720was performed.
Immunological evaluation
Five days post-transplantation, the spleens, axillary
lymph nodes (ALNs) and skin allografts were harvested
from the recipient mice. Single-cell suspensions from the
spleen, ALNs and skin were counted in a Neubauer
chamber. The spleen cells were used for in vitro stimulation
and qPCR analysis, whereas the ALNs and graft-infiltrating
cells were evaluated by flow cytometry.
Flow cytometry
Cell suspensions (16106) from the ALNs and grafts were
incubated for 30 min with rat anti-mouse monoclonal anti-
body CD4PerCP-Cy5.5 (eBioscience, San Diego, CA, USA).
After this period, the cells were washed with PBS, fixed for
15 min with 1% paraformaldehyde, permeabilized for 6 min
with 0.2% Triton X-100 and stainedwith rat anti-mouse Foxp3
FITC for 30 min (eBioscience, San Diego, CA, USA). The
stained cells were acquired in a FACSCalibur FlowCytometer
(BD Biosciences, San Jose, CA, USA), and the data were
analyzed using Cell Quest Pro software (BD Biosciences). At
least 30,000 events were acquired for each analysis.
Quantitative analysis of gene expression by real-
time PCR
The total RNA from the skin graft and spleen cells was
extracted with Trizol (Invitrogen Life Technologies) according
to themanufacturer’s instructions and reverse-transcribed into
complementary DNA with Superscript III (Invitrogen Life
Technologies). For the real-time PCR of the IL-10, IL-6, FOXP3,
IL-23 and IL-27 genes, 0.5 mL of primer, 1 mL of cDNA, 3.5 mL
of RNAse/DNAse-free water and 5 mL of Taqman Fast
Universal Master Mix (Applied BiosystemsH) were used. The
PCR was performed in an Applied Biosystems 7900HT Fast
Real-Time PCR SystemH. The mRNA level was determined
following normalization to b-actin. We performed qPCR in the
spleen for IL-10, IL-6, FOXP3, IL-23 and IL-27. In the skin graft,
we performed qPCR for IL-10, FOXP3, IL-23 and IL-27.
Bio-Plex
The spleen cells were harvested at day five post-skin
transplantation and stimulated in vitro with anti-CD3. A
Bio-Plex mouse cytokine assay kit (Bio-Rad Laboratories,
Hercules, CA, USA) was used to test the samples for the
presence of the specific cytokines IL-10, IL-6 and IL-17. The
assay was performed in the Bio-Plex suspension array
system, and the data were analyzed using Bio-Plex Manager
software version 4.0. The standard curves ranged from 1.95
to 32 000 pg/ml.
Figure 2 - Evaluation of the effect of transplantation and FTY720 treatment on draining lymph nodes (axillary) five days after F1 skin
graft transplantation in the C57BL/6 mice. A - FTY720 treatment reduces the number of lymph node cells (p=0.022). B - FTY720
treatment reduces the percentage of cells (p=0.028) with the Treg phenotype (CD4+Foxp3+). The results are expressed as the means¡
SD.
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Statistical analysis
The skin allograft survival curve was obtained using the
Kaplan-Meier method. Other data were expressed as the
means¡SD. The statistical analyses were performed using
Graph Pad Prism version 5.00 for Windows (Graph Pad Soft-
ware, SanDiego,CA,USA). Theparametric Student’s t testwas
employed, and p-values,0.05 were considered significant.
RESULTS
Treatment with FTY720 increases skin allograft
survival
To evaluate the effect of FTY720 on the progression of skin
allograft rejection, the recipient mice were either transplanted
only (Tx, n= 5) or transplanted and submitted to the daily
Figure 3 - Evaluation of graft-infiltrating cells five days after F1 skin graft transplantation in the C57BL/6 mice. A - A representative flow
cytometry dot plot showing the graft-infiltrating cells (FSC x SSC) and Treg cells (CD4+Foxp3+). B - FTY720 treatment reduces the
number of graft-infiltrating cells in the F1 transplanted skin (p=0.02). C - FTY720 treatment reduces the percentage of CD4+ (p=0.014)
graft-infiltrating cells in the F1 transplanted skin. D - FTY720 reduces but does not prevent the accumulation of Foxp3+ graft-infiltrating
cells in the F1 transplanted skin (p=0.011). The results are expressed as the means ¡ SD.
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administration of FTY720 (Tx + FTY, n= 5) by gavage for
21 days, starting three days before the transplantation. We
observed a significant (p-value= 0.0047) increase in the
survival of allografts from F1 mice (BALB/c x C57BL/6)
when the recipient C57BL/6 mice were treated with FTY720
(Figure 1A). The macroscopic examination shows that the
first rejection (90% of skin necrosis) occurred on day 13 for
the FTY720-treated mice, whereas the first rejection occurred
as early as 9 days after transplantation in the non-treated
mice (Figure 1B).
FTY720 reduced the number of cells in the lymph
nodes
The total number of cells and percentage of regulatory T
cells were analyzed in the lymph nodes from the Tx and Tx +
FTY mice five days post-transplantation. Our results showed
that the FTY720 treatment was able to significantly reduce
both the number of cells and percentage of CD4+Foxp3+ T
cells in the lymph nodes (Figure 2).
FTY720 reduced the number of graft-infiltrating
cells
Five days after the skin transplantation, we analyzed the
graft-infiltrating cells and observed that the FTY720 treat-
ment reduced the number of graft-infiltrating cells and
diminished the percentage of CD4+ T cells in the skin
allograft. The FTY720 did not prevent the accumulation of
Foxp3+ cells in the graft but did cause a decrease in the
percentage of these cells (Figure 3).
Decrease in the cytokine levels in mice treated with
FTY720
We evaluated the cytokine levels in the spleen cells
submitted to in vitro stimulation with anti-CD3. The analysis
of the 72-h culture supernatants by Bio-Plex showed
decreased levels of IL-10, IL-6 and IL-17 secretion in the
FTY720-treated mice compared with the non-treated mice
(Figure 4). The IL-6 secretion was significantly decreased in
the Tx+FTY group (p,0.05).
qPCR analysis
To confirm our results regarding cytokine levels, we
evaluated the IL-10, IL-6, FOXP3, IL-23 and IL-27 gene
expression in the spleen cells by real-time PCR. In
agreement with our previous observation, there was a
decrease in the IL-10 and IL-6 mRNA levels in the
splenocytes of the FTY720-treated mice. In this group, we
also observed a decrease in the IL-23 mRNA level but an
increase in the IL-27 mRNA level. The FOXP3 expression
was decreased, but this decrease did not reach statistical
significance (Figure 5).
In the skin, we found increased mRNA levels of IL-10, IL-
27, and IL-23 in mice treated with FTY720 (Figure 6), but this
increase was not statistically significant. The FOXP3
expression was decreased in this group (p= 0.0948).
DISCUSSION
In the present study, we investigated the events asso-
ciated with FTY720 treatment in mice submitted to skin
Figure 4 - FTY720 decreases the cytokine production by splenocytes. Analysis of the IL-10, IL-6 and IL-17 secretion levels by the
splenocytes. The spleen cells from the Tx non-treated and Tx + FTY720-treated mice were harvested at day 5 post-skin transplantation
and stimulated in vitro with anti-CD3. The supernatants were collected 72 h later, and the IL-10, IL-6, and IL-17 levels were determined
by multiplex ELISA. The results are expressed as the means ¡ SD (*p,0.05).
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allograft transplantation. We confirmed the previous data
showing increased skin allograft survival and delayed
macroscopic signs of tissue necrosis in the mice treated
with FTY720. In the same model, we showed previously that
FTY720 increases skin allograft survival when administered
as monotherapy, as well as when combined with cyclos-
porine, tacrolimus and sirolimus (22-25).
The prevention of T lymphocytes from migrating to
inflammatory sites is an effect already described for FTY720.
Accordingly, our present results demonstrate a reduction in
the number of graft-infiltrating cells and in the percentage
of CD4+ T and Foxp3+ cells.
In 2008, we demonstrated that the increased skin allograft
survival in FTY720-treated mice was associated with
diminished cell numbers in the spleen, blood and axillary
lymph nodes (24). Our present results showed a reduction
in the number of cells and percentage of CD4+Foxp3+ cells in
the lymph nodes of mice treated with FTY720.
Recently, we demonstrated that FTY720 was effective in
suppressing experimental autoimmune uveitis (EAU), and
this finding was associated with a reduction in the eye-
infiltrating cells with either Treg or Th17 phenotypes (26). In
the present study, at the early time points (day +5) after
transplantation, FOXP3 gene expression in the spleen and
Figure 5 - FTY720-treated mice exhibit a decrease in the relative gene expression (qPCR analysis) of IL-10, IL-6, and IL-23 in the spleen
cells, whereas IL-27 is increased. The relative gene expression in the spleen cells was evaluated in the Tx non-treated and Tx + FTY720-
treated mice. The results are expressed as the means ¡ SD.
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skin graft, as well as Foxp3 protein expression in the
lymph nodes and graft-infiltrating cells, was decreased in
mice treated with FTY720. These findings show that
FTY720 does not inhibit but rather decreases the expres-
sion of Foxp3 systemically. The increase in skin allog-
raft survival due to FTY720 without reaching indefinite
tolerance could be justified by the following: the increased
skin graft survival induced by FTY720 is mediated by other
factors in addition to Foxp3 cells; and the decreased Foxp3
expression contributes to the rejection, even if over the
long-term.
In our model, the in vitro anti-CD3 stimulation of
splenocytes from the mice submitted to skin transplanta-
tion and treated with FTY720 exhibited decreased secretion
of IL-10 and IL-6, which was confirmed by qPCR analysis.
In addition, the splenocytes from FTY720-treated mice
secreted significantly less IL-17 after in vitro anti-CD3
stimulation, and the evaluation of the mRNA in the spleen
cells showed a decreased level of IL-23. Chen et al. showed
an enhanced expression of Th17-related cytokines at the
early stage of cornea rejection either in the draining lymph
nodes (LNs) or in the allograft. They also found that
responder cells in the draining LNs of the transplanted
recipients secreted high levels of IL-6, TGF-b and IL-21
compared with the controls and suggested that these
factors could drive naı¨ve T cells to differentiate into Th17
cells (27). Because Th17 cells have been implicated in renal
allograft rejection (28) and IL-17 production has been
shown to be dependent on IL-6 (29) and IL-23 levels (30),
the decreased expression of these cytokines in our model
suggests that the prolonged skin allograft survival obtained
by FTY720 treatment was at least in part due to Th17
phenotype impairment in the periphery rather than Foxp3
enhancement. In agreement, Mehling et al. showed a
decrease in the number of Th17 cells from the blood of
patients with multiple sclerosis treated with FTY720 and of
patients in disease remission (31). However, whether
FTY720 increases the Treg cell population is still uncertain.
Wolf et al. showed in vitro and in vivo that FTY720 inhibits
the proliferation of Treg cells without affecting their
viability, phenotype or in vitro immunosuppression (32).
Zhou et al. showed that the addition of FTY720 to the
mixed lymphocyte reaction (MLR) in mouse (BALB/c
and C57BL/6) splenocytes increased the proportion of
CD4+CD25+ T regulatory cells. Additionally, FTY720 added
to the MLR caused the suppression of lymphocyte pro-
liferation, decreased the IL-2 levels in the supernatant, and
induced lymphocyte apoptosis (33).
Allograft acceptance/rejection is associated with multiple
suppressor/effector mechanisms, and immunosuppressive
drugs administered during transplantation have been
shown to affect T cell populations.
In agreement, Hester et al. observed, in the follow-up of
kidney recipients induced with alemtuzumab and treated
post-transplantation with several drugs such as sirolimus or
sirolimus + mycophenolate mofetil, that rejection and the
long-term maintenance of immunosuppression influence
the number of circulating Treg and Th17 cells (34).
Figure 6 - FTY720-treated mice present an increase in the relative gene expression (qPCR analysis) of IL-10, IL-23, and IL-27 in the skin
grafts. The relative gene expression (qPCR analysis) of FOXP3, IL-10, IL-23, and IL-27 in the F1 skin grafts was evaluated in the Tx non-
treated and Tx + FTY720-treated mice. The results are expressed as the means ¡ SD.
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Sewgobind et al. (35) showed that the relative mRNA
expression of FOXP3 decreased in the blood of kidney-
transplanted patients treated with rabbit anti-thymocyte
globulin (rATG) or rATG + tacrolimus, whereas the levels of
IL-10 and IL-27p28 increased compared with the levels in
non-transplanted blood donors.
Battaglia et al. (36) showed that the administration of IL-
10 in combination with the immunosuppressive drug
rapamycin promoted tolerance in type 1 diabetic mice after
pancreatic islet transplantation by the induction of Tr1 cells.
In addition, IL-27 secretion from dendritic cells has been
shown to enhance the development of Tr1 cells and, as
observed by Yoshimoto et al. (37), inhibit not only Th2
commitment but also Th2 cytokine production from already
polarized Th2 cells (down-regulation of GATA-3 and up-
regulation of T-bet). Moreover, IL-27 was shown by
Stumhofer et al. (38) to directly antagonize the development
of the Th17-cell responses in experimental autoimmune
models.
In our model, even though statistical significance could
not be reached among groups, the prolonged skin allograft
survival promoted by FTY720 treatment could be explained
by the increased expression of IL-10 and IL-27 in the skin
graft, suggesting the development of the Tr1 cells. However,
we also found an increase in the IL-23 expression in the skin
graft, confirming the presence of Th17 cells. In agreement
with our data, Li et al. (39) found both Treg and Th17 cells in
mouse liver transplants. They showed a time-dependent
and significant increase in Th17-related cytokines (IL-17, IL-
6 and IL-23), whereas the expression of Treg-related
cytokines (IL-10, TGF-b1) was markedly low in the liver of
transplanted mice prior to graft rejection.
Our results show that FTY720 treatment causes a different
modulation of IL-10 and IL-23 in the spleen and skin graft;
namely, the IL-10 and IL-23 expression decreased in the
spleen but increased in the graft. In contrast, IL-27 and
Foxp3 exhibited the same modulation in the spleen and
skin, with an increase in IL-27 and decrease in Foxp3. These
findings suggest that, at early time points (day +5) after
transplantation, FTY720 controls the balance between Tr1
(IL-10 and IL-27) and Th17 (IL-23) in the graft, which
prevents rejection for a definite period of time.
In conclusion, we demonstrated that skin allograft
survival was prolonged but not indefinite in FTY720-treated
mice, indicating that the drug did not prevent the long-term
imbalance between the Treg and Th17 cells in the graft,
which thus led to rejection.
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